Dublin, Jan. 09, 2017 -- Research and Markets has announced the addition of the "Microfluidics Market by Component (Microfluidic Chips, Micropump, Microneedle), Material (Polymer, Glass, Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, Clinical, Environmental, Drug Delivery) - Global Forecast to 2021" report to their offering.
The global microfluidics market is projected to reach USD 8.78 billion by 2021 from USD 3.65 billion in 2016, growing at a CAGR of 19.2% during the forecast period.
The report provides a detailed analysis of microfluidics market. It aims at estimating the market size and future growth potential of this market across different segments such as components, application, materials, and regions. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.
Over the past five years, the microfluidics market has witnessed tremendous growth primarily due to rising demand for point-of-care (POC) testing, increasing use of miniaturized microfluidic chips to achieve faster testing and improved portability, and increased prevalence of age-related and lifestyle diseases and disorders.
The market is mainly driven by the rising geriatric population, growing Asian healthcare market, and upsurge in government and corporate funding for R&D. However, lack of adequate healthcare and research infrastructure in emerging markets, dearth of skilled professionals in clinical laboratories, and high prices of integrated instruments and microfluidics chips are hampering the growth of this market to a certain extent.
The global microfluidics market is highly fragmented; some of the major players in this market:
- Agilent Technologies
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Danaher Corporation
- Dolomite Microfluidics
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Perkinelmer, Inc.
- Raindance Technologies, Inc.
- Thermo Fisher Scientific Inc.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Microfluidics Market, By Component
8 Microfluidics Market, By Material
9 Microfluidics Market, By Application
10 Global Microfluidics Market, By Region
11 Competitive Landscape
12 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/c4pvmj/microfluidics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


OpenAI Explores Massive Funding Round at $750 Billion Valuation
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



